Pretransplant Neutropenia Is Associated with Poor-Risk Cytogenetic Features and Increased Infection-Related Mortality in Patients with Myelodysplastic Syndromes

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 7, 2008, Pages 799-806

  Scott, Bart L ^a,b   Park, J Y ^c   Deeg, H Joachim ^a,b   Marr, Kieren A ^a,d   Boeckh, Michael ^a,b   Chauncey, Thomas R ^a,b,e   Appelbaum, Frederick R ^a,b   Storb, Rainer ^a,b   Storer, Barry E ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Kangdong Sacred Heart Hospital   (South Korea)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

MDS; Neutropenia; Stem cell transplant

Indexed keywords

ATOVAQUONE; BUSULFAN; CEFTAZIDIME; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; FLUCONAZOLE; FLUDARABINE; ITRACONAZOLE; LEVOFLOXACIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANDIDIASIS; CHILD; COHORT ANALYSIS; CYTOGENETICS; FEMALE; GRAFT VERSUS HOST REACTION; GRAM POSITIVE BACTERIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; SCORING SYSTEM; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS INFECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; MYCOSES; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; ODDS RATIO; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 44649102568     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.04.011     Document Type: Article

References (27)

1. Dale D.C. Neutropenia and neutrophilia. In: Lichtman M.A., Beutler E., Kipps T.J., Seligsohn U., Kaushansky K., and Prchal J.T. (Eds). Williams Hematology (2006), McGraw-Hill, New York 907-919
2. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood 1998;91:1100). Blood 89 (1997) 2079-2088
3. Engels E.A., Ellis C.A., Supran S.E., et al. Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis 28 (1999) 256-266
4. Viscoli C., Varnier O., and Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 40 Suppl 4 (2005) S240-S245
5. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
6. Yamaguchi N., Ito Y., and Ohyashiki K. Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes. Ann Hematol 84 (2005) 383-388
7. Mühlemann K., Wenger C., Zenhäusern R., and Täuber M.G. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 19 (2005) 545-550
8. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
9. Anderson J.E., Appelbaum F.R., Fisher L.D., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82 (1993) 677-681
10. Anderson J.E., Appelbaum F.R., Schoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14 (1996) 220-226
11. Jurado M., Deeg H.J., Storer B., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 8 (2002) 161-169
12. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan before transplantation of allogeneic hematopoietic stem cells. Blood 100 Part 1 (2002) 213a
13. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107 (2006) 2184-2191
14. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
15. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
16. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 57 (1981) 267-276
17. Flowers M.E.D., Traina F., Storer B., et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. [erratum appears in Bone Marrow Transplant. 2005;35:535]. Bone Marrow Transplant 35 (2005) 277-282
18. Sangiolo D., Storer B., Nash R., et al. Toxicity and efficacy of daily Dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant 11 (2005) 521-529
19. Marr K.A., Crippa F., Leisenring W., et al. Itraconazole versus fluconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 103 (2004) 1527-1533
20. Hakki M., Limaye A.P., Kim H.W., Kirby K.A., Corey L., and Boeckh M. Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation. Bone Marrow Transplant 39 (2007) 687-693
21. Crippa F., Holmberg L., Carter R.A., et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 8 (2002) 281-289
22. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 7-14
23. Deeg H.J., Shulman H.M., Anderson J.E., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95 (2000) 1188-1194
24. Sievers E.L., Lange B.J., Buckley J.D., et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 88 (1996) 1483-1488
25. Gooley T.A., Martin P.J., Fisher L.D., and Pettinger M. Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Controlled Clin Trials 15 (1994) 450-462
26. Chien JW, Boeckh M, Hansen JA, Clark JG. Lipopolysaccharide binding protein promoter variants influence the risk for gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood; prepublished online December 3, 2007; DOI 10.1182/blood-2007-09-101709.
27. Marr K.A., Carter R.A., Boeckh M., Martin P., and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366